Novel therapeutic agents for B-cell lymphoma: Developing rational combinations

Craig B. Reeder, Stephen M. Ansell

Research output: Contribution to journalReview article

38 Scopus citations

Abstract

Several novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.

Original languageEnglish (US)
Pages (from-to)1453-1462
Number of pages10
JournalBlood
Volume117
Issue number5
DOIs
StatePublished - Feb 3 2011

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this